-
Share
21,661 Posts.
886
08/04/20
07:58
Share
IMO
Nothing wrong here - normal biotech business
CR's are always a constant with biotechs - hitting the market constantly for cash is nothing new in this game
The 30 patient data does not imo seem strong enough to merit a CR at well above market
Capital raises between inflection points only benefits a select few
Newbies note - we were told that no cash required until 1st Half 2021 - unreal and misleading statements. imo
DYOR
-